RxDoctor Payments Data

David Ibrahim, MD

Family Medicine · Decatur, ILNPI 1225443542

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $76,370 of the $76,520 with a category attached, or 99.8%. CSL Plasma Inc. accounts for 99.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $59,500, more than ten times the $137 reported in 2019. Among family medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$76,520in general payments, 2019–2025

Across 175 payments — averaging $437.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Plasma Inc.$76K
  • AstraZeneca$69
  • Vapotherm Inc$24
  • AbbVie$19
  • Merck$15
  • Microport Orthopedics Inc$12
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$76,370100%
  • Food & beverage$1500%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$76,520 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$274,623
Medicare patients
811
Services billed
2,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate12$73,345
EliquisApixaban91$36,597
JanuviaSitagliptin Phosphate60$18,282
BriviactBrivaracetam17$16,383
MounjaroTirzepatide15$16,359
OzempicSemaglutide13$12,714
LinzessLinaclotide20$11,457
FycompaPerampanel18$10,864
Incruse ElliptaUmeclidinium Bromide19$7,226
FarxigaDapagliflozin Propanediol12$6,441
Famotidine180$5,866
JardianceEmpagliflozin14$5,797
Fluticasone-VilanterolFluticasone/Vilanterol15$5,591
Atorvastatin Calcium316$5,495
Levetiracetam95$5,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$18,28260 claims
AbbVieLinzess$19$11,45720 claims
AstraZenecaFarxiga$69$6,44112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Decatur

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →